A Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension



Status:Recruiting
Conditions:Insomnia Sleep Studies
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 75
Updated:4/5/2019
Start Date:November 27, 2018
End Date:September 2020
Contact:Director Disclosure & Transparency
Email:ClinicalTrialDisclosure@JazzPharma.com
Phone:2158323750

Use our guide to learn which trials are right for you!

A Double-blind, Placebo-controlled, Randomized Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in the Treatment of Idiopathic Hypersomnia (IH) With an Open-label Safety Extension

This is a study of the efficacy and safety of JZP-258, an oxybate mixed-salts oral solution
being developed as a low sodium alternative product for Xyrem.


Inclusion Criteria:

1. Male or female between 18 and 75 years of age, inclusive, at the time of consent.

2. Have a primary diagnosis of IH according to the International Classification of Sleep
Disorders ICSD-2 or ICSD-3 criteria.

3. At the Screening Visit and the Baseline Visit, subjects who are not on Xyrem at study
entry must have ESS scores ≥ 11 (as assessed with a look-back period of 1 week).

4. If currently treated with Xyrem, must have documented clinical improvement of EDS
after the initiation of Xyrem per Investigator's clinical judgment.

5. Average nightly total sleep time of ≥ 7 hours, per subject history. Average nightly
total sleep time will be confirmed by Investigator's review of sleep diaries collected
during the final 2 weeks of the Screening Period.

6. If currently treated with stimulants and / or alerting agents or nicotine replacement
therapy, must have been taking the same regimen and dose for at least 2 months prior
to screening and must agree to take the same dose leading up to and throughout the
Double-blind Randomized Withdrawal Period.

7. Have used a medically acceptable method of contraception for at least 2 months prior
to the first dose of study drug and consent to use a medically acceptable method of
contraception from the first dose of study drug, throughout the entire study period,
and for 90 days after the last dose of study drug.

Exclusion Criteria:

1. Hypersomnia due to another medical, behavioral, or psychiatric disorder condition.

2. Evidence of untreated or inadequately treated sleep-disordered breathing.

3. Clinically significant parasomnias (eg, sleep walking, rapid eye movement sleep
behavior disorder, etc.).

4. Current or past (within 1 year) major depressive episode according to DSM-5 criteria.
Patients with depression under control are allowed per the judgment of the
Investigator or the treating physician and the anti-depressant treatment has to be
stable for at least 6 months prior to Screening and remain stable for the duration of
the study.

5. Current suicidal risk as determined from history by presence of active suicidal
ideation as indicated by positive response to item #4 or #5 on C-SSRS, or any history
of suicide attempt.

6. Occupation requiring nighttime shift work or variable shift work with early work start
times or other occupations that could affect the safety of the subject per the
judgment of the Investigator.

7. Treatment or planned treatment with any CNS sedating agents, including but not limited
to benzodiazepines or other sedating anxiolytics, sedating antidepressants, hypnotics,
sedatives, neuroleptics, opoids, barbiturates, phenytoin, melatonin, ethosuximide,
medications containing valproic acid or its sodium salt, or any other medication in
which the subject experiences sedation are prohibited during the study. Treatment must
have been discontinued within 2 weeks or 5 half-lives, whichever is longer, prior to
enrollment. The Investigator must ensure that discontinuation from these medications
is medically supervised. Subjects must abstain from these medications during the
study.

8. Current or past substance use disorder (including alcohol) according to DSM-5
criteria, or the subject is unwilling to refrain from consuming alcohol, cannabinoids,
or prohibited medications during the study.
We found this trial at
12
sites
1000 Alpine
Boulder, Colorado 80304
303-443-7229
?
mi
from
Boulder, CO
Click here to add this to my saved trials
Atlanta, Georgia 30342
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Austin, Texas 78703
?
mi
from
Austin, TX
Click here to add this to my saved trials
Charlotte, North Carolina 28207
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Colorado Springs, Colorado 80918
?
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
1333 Taylor Street
Columbia, South Carolina 29201
?
mi
from
Columbia, SC
Click here to add this to my saved trials
?
mi
from
Dublin, OH
Click here to add this to my saved trials
Gastonia, North Carolina 28054
?
mi
from
Gastonia, NC
Click here to add this to my saved trials
Mooresville, North Carolina 28117
?
mi
from
Mooresville, NC
Click here to add this to my saved trials
180 Wingo Way
Mount Pleasant, South Carolina 29464
?
mi
from
Mount Pleasant, SC
Click here to add this to my saved trials
Saint Louis, Missouri 63143
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Antonio, Texas 78229
?
mi
from
San Antonio, TX
Click here to add this to my saved trials